First Horizon Corp Purchases 13,857 Shares of Amgen Inc. $AMGN

First Horizon Corp increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 27.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 64,675 shares of the medical research company’s stock after buying an additional 13,857 shares during the quarter. Amgen accounts for approximately 1.0% of First Horizon Corp’s holdings, making the stock its 28th largest holding. First Horizon Corp’s holdings in Amgen were worth $22,756,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the stock. High Note Wealth LLC increased its holdings in Amgen by 5.8% during the 4th quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock worth $166,000 after purchasing an additional 28 shares in the last quarter. TAGStone Capital Inc. lifted its stake in Amgen by 0.7% in the fourth quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock valued at $1,351,000 after acquiring an additional 28 shares during the last quarter. Verus Capital Partners LLC lifted its stake in Amgen by 2.3% in the 4th quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company’s stock valued at $403,000 after purchasing an additional 28 shares during the last quarter. Destination Wealth Management raised its stake in Amgen by 2.1% in the 4th quarter. Destination Wealth Management now owns 1,393 shares of the medical research company’s stock valued at $456,000 after acquiring an additional 29 shares during the period. Finally, Breakwater Capital Group raised its stake in Amgen by 1.4% in the 1st quarter. Breakwater Capital Group now owns 2,039 shares of the medical research company’s stock valued at $717,000 after acquiring an additional 29 shares during the period. Institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on AMGN. Erste Group Bank reaffirmed a “hold” rating on shares of Amgen in a research report on Tuesday, May 5th. Truist Financial increased their price objective on shares of Amgen from $327.00 to $340.00 and gave the company a “hold” rating in a research report on Tuesday. BMO Capital Markets restated an “outperform” rating and set a $400.00 target price on shares of Amgen in a research note on Wednesday, July 1st. UBS Group upped their price target on shares of Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Finally, Royal Bank Of Canada reissued a “positive” rating on shares of Amgen in a report on Thursday, June 18th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $355.73.

Amgen Stock Down 1.2%

Shares of AMGN opened at $363.62 on Friday. The firm’s 50 day moving average is $344.30 and its 200-day moving average is $349.22. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $391.29. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The stock has a market capitalization of $196.25 billion, a PE ratio of 25.30, a P/E/G ratio of 3.63 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The firm had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company’s revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the company posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities research analysts forecast that Amgen Inc. will post 22.32 EPS for the current year.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.85% of the stock is currently owned by corporate insiders.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.